Mahana Therapeutics receives permanent reimbursement in Germany for Cara Care IBS, a digital therapeutic solution.

Mahana Therapeutics secures permanent reimbursement in Germany for Cara Care IBS, a digital therapeutic solution. Now accessible to all IBS patients, the reimbursement allows the solution to be prescribed and re-prescribed for 90 days and is aligned with medical guidelines. It can be used alongside or without standard care therapies and is based on a randomized controlled clinical trial of 378 patients.